Target Name: MDC1
NCBI ID: G9656
Review Report on MDC1 Target / Biomarker Content of Review Report on MDC1 Target / Biomarker
MDC1
Other Name(s): MDC1_HUMAN | nuclear factor with BRCT domains 1 | KIAA0170 | Mediator of DNA damage checkpoint 1 | Homologue to Drosophila photoreceptor protein calphotin | Mediator of DNA damage checkpoint protein 1 | homologue to Drosophila photoreceptor protein calphotin | Nuclear factor with BRCT domains 1 | DKFZp781A0122 | MGC166888 | NFBD1 | mediator of DNA damage checkpoint 1

MDC1: A Protein Involved in Cancer, Fibrosis and COPD

MDC1 (MDC1_HUMAN), also known as cancer-associated fibrosis (CAF), is a protein that is expressed in various tissues and cells throughout the body, including epithelial, muscle, and connective tissue. It is a key player in the regulation of extracellular matrix (ECM) degradation and cell-cell adhesion, and has been implicated in a wide range of diseases, including cancer, fibrosis, and chronic obstructive pulmonary disease (COPD).

Despite its importance, MDC1 has remained a relatively unstudied protein. However, recent studies have identified MDC1 as a potential drug target and biomarker for a variety of diseases. In this article, we will explore the biology and potential therapeutic applications of MDC1, with a focus on its role as a drug target and biomarker.

The biology of MDC1

MDC1 is a 20-kDa protein that is expressed in various tissues and cells throughout the body. It is a member of the integrin family, which is involved in cell-cell adhesion and migration. MDC1 is involved in the regulation of ECM degradation and cell-cell adhesion, and has been implicated in a wide range of diseases, including cancer, fibrosis, and COPD.

One of the key functions of MDC1 is its role in the regulation of ECM degradation. ECM is a complex structure that is composed of extracellular matrix (ECM) components that are derived from cells and other tissues. ECM components include proteins, carbohydrates, and nucleic acids, which are involved in various cellular processes, including cell adhesion, migration, and signaling.

MDC1 is involved in the regulation of ECM degradation by promoting the degradation of ECM components that are no longer needed by the cell. This process is critical for maintaining the integrity of the ECM and for the proper functioning of cells. In addition, MDC1 is involved in the regulation of cell-cell adhesion by controlling the distribution of ECM components on the cell surface.

MDC1 has also been implicated in the regulation of various signaling pathways that are involved in cancer, fibrosis, and COPD. For example, MDC1 has been shown to be involved in the regulation of the TGF-β pathway, a pathway that is involved in cell growth, differentiation, and angiogenesis. In addition, MDC1 has been shown to be involved in the regulation of the NF-kappa-B pathway, a pathway that is involved in inflammation and stress responses.

Potential therapeutic applications of MDC1

Despite its importance, MDC1 has remained a relatively unstudied protein. However, recent studies have identified MDC1 as a potential drug target and biomarker for a variety of diseases. In this section, we will explore the potential therapeutic applications of MDC1, with a focus on its role as a drug target and biomarker.

Drug targeting of MDC1

MDC1 is a potential drug target due to its involvement in various signaling pathways that are involved in cancer, fibrosis, and COPD. In addition, MDC1 has been shown to be involved in the regulation of ECM degradation, which is an important process for maintaining the integrity of tissues and organs.

One potential approach to targeting MDC1 is to use small molecules that can modulate its activity. For example, researchers have shown that inhibitors of the tyrosine kinase receptor (TKR) can be effective in inhibiting MDC1 activity and preventing the regulation of ECM degradation. In addition, inhibitors of the protein kinase B (PKB) have also been shown to be effective in inhibiting MDC1 activity.

Another potential approach to targeting MDC1 is to use antibodies that can specifically recognize and target its extracellular domain. For example, researchers have shown that antibodies that recognize the extracellular domain of MDC1 can be effective in inhibiting its activity and preventing the regulation of ECM degradation.

MDC1 as a biomarker

In addition to its potential as a drug target, MDC1 has also been identified as a potential biomarker for a variety of diseases. For example, researchers have shown that levels of MDC1 are elevated in various tissues and cells

Protein Name: Mediator Of DNA Damage Checkpoint 1

Functions: Required for checkpoint mediated cell cycle arrest in response to DNA damage within both the S phase and G2/M phases of the cell cycle. May serve as a scaffold for the recruitment of DNA repair and signal transduction proteins to discrete foci of DNA damage marked by 'Ser-139' phosphorylation of histone H2AX. Also required for downstream events subsequent to the recruitment of these proteins. These include phosphorylation and activation of the ATM, CHEK1 and CHEK2 kinases, and stabilization of TP53 and apoptosis. ATM and CHEK2 may also be activated independently by a parallel pathway mediated by TP53BP1

The "MDC1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MDC1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

MDFI | MDFIC | MDGA1 | MDGA2 | MDH1 | MDH1B | MDH2 | MDK | MDM1 | MDM2 | MDM4 | MDN1 | MDS2 | ME1 | ME2 | ME3 | MEA1 | MEAF6 | MEAF6P1 | MEAK7 | Mechanoelectrical transducer (MET) channel | Mechanosensitive Ion Channel | MECOM | MECOM-AS1 | MeCP1 histone deacetylase (HDAC) complex | MECP2 | MECR | MED1 | MED10 | MED11 | MED12 | MED12L | MED13 | MED13L | MED14 | MED14P1 | MED15 | MED15P8 | MED16 | MED17 | MED18 | MED19 | MED20 | MED21 | MED22 | MED23 | MED24 | MED25 | MED26 | MED27 | MED28 | MED29 | MED30 | MED31 | MED4 | MED4-AS1 | MED6 | MED7 | MED8 | MED9 | MEDAG | Mediator Complex | Mediator of RNA Polymerase II Transcription | MEF2A | MEF2B | MEF2C | MEF2C-AS1 | MEF2C-AS2 | MEF2D | MEFV | MEG3 | MEG8 | MEG9 | MEGF10 | MEGF11 | MEGF6 | MEGF8 | MEGF9 | MEI1 | MEI4 | MEIG1 | MEIKIN | MEIOB | MEIOC | MEIOSIN | MEIS1 | MEIS1-AS2 | MEIS1-AS3 | MEIS2 | MEIS3 | MEIS3P1 | MEIS3P2 | Melanin | Melanin-concentrating hormone (MCH) receptor | Melanocortin receptor | Melanoma-Associated Antigen | Melatonin receptor | MELK | MELTF | MELTF-AS1